SOURCE: Spotlight Innovation Inc.

Spotlight Innovation Inc.

August 24, 2015 08:00 ET

Spotlight Innovation Subsidiary Celtic Biotech Prepares to Start Part 2 of Phase I Intravenous Crotoxin Clinical Study

WEST DES MOINES, IA--(Marketwired - Aug 24, 2015) - Spotlight Innovation Inc. (OTCQB: STLT) announces today that its subsidiary Celtic Biotech has started preparations to conduct Part 2 of the Phase I clinical study, Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration. Crotoxin is a neurotoxin derived from the venom of the South American rattlesnake Crotalus durissus and is Celtic Biotech's lead drug.

Dr. Paul Reid, President of Celtic Biotech, said "We are gratified that Phase I Part 1 of the study was completed. Our Contract Research Organization for the Paris, France-based study, ImmunoClin Ltd., conducted the innovative trial design. The study went as planned and was monitored to international regulatory standards of good clinical practice. The clinical data is now being assembled and organized in preparation for analysis by a scientific review committee as mandated by the protocol. We expect results from the review committee to be available on or about November 2015. In the expectation that the scientific review will be successful, we have begun taking the steps necessary to initiate Part 2 of the study, which we anticipate will begin in January 2016."

"The completion of this clinical trial phase is a significant milestone," said Cris Grunewald, President and CEO of Spotlight Innovation. "Moving Crotoxin successfully through the clinical trial process is a high priority. It is our hope that these clinical trials will eventually lead to significant help for people with lung, breast and skin cancers. The American Cancer Society estimates that over two hundred thousand Americans alone will die from these cancers in 2015."

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies, acquires and incubates companies that have unique intellectual property (IP) in the medical sector. The Company has relationships with the nation's leading academic and institutional IP developers, and locates promising IP technologies with potential for market share capture. With strong support, development, resources and strategic planning expertise, we believe we can develop IP that will have a positive effect on healthcare. We partner with proven sector leaders on commercialization once technologies are fully developed. Additional information available at www.spotlightinnovation.com.

About Celtic Biotech Iowa, Inc.

Celtic Biotech Iowa, Inc., a subsidiary of Spotlight Innovation Inc., is developing novel, clinical trial-phase products for the treatment of cancers and pain in humans. Derived from naturally specialized receptor-binding proteins, these products have the potential to reduce treatment costs, increase survivability, and improve the quality-of life for cancer patients. Additional information available at www.celticbiotech.com.

About the ImmunoClin Corporation

ImmunoClin Corporation (OTCQB: IMCL) is a United States healthcare company with principal office in Washington DC, European headquarters and laboratories in central London, United Kingdom. IMCL's subsidiary, ImmunoClin Ltd, has been providing quality research and development services to industry for over 14 years. More information available at www.immunoclin.com.

Forward Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Contact Information

  • Press Contact
    Rene Erickson
    Spotlight Innovation Inc.
    1-515-274-9087
    corpcomm@spotlightinnovation.com

    Investor Contact
    Rudy Barrio
    DresnerAllenCaron
    1-212-691-8087
    r.barrio@allencaron.com

    Photographs of Crotalus durissus are available for the media upon request from DresnerAllenCaron by contacting Rudy Barrio at 212-691-8087.